Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 9, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Is HBsAg quantification ready, for prime time?

Stéphane Chevaliez1

  • 1Inserm U955, Department of Virology, Université Paris-Est, French National Reference Center for Viral Hepatitis B, C and delta, hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.

Clinics and Research in Hepatology and Gastroenterology
|August 13, 2013
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dried Blood Spot: A Tool to Ensure Broad Access to Hepatitis D Screening, Diagnosis, and Treatment Monitoring.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Delta Describe, the French Collaborative Project: The Profile and Management of Hepatitis Delta Patients in Metropolitan France.

Viruses·2026
Same author

Hepatitis D Virus Seroconversion Rate Among People With Chronic Hepatitis B Virus Infection in France and The Gambia (Inci-D).

Open forum infectious diseases·2026
Same author

The Viral Hepatitis Prevention Board (VHPB) supports the continued recommendation for universal hepatitis B vaccination of all newborns within 24 hours of birth.

Human vaccines & immunotherapeutics·2025
Same author

Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.

Journal of hepatology·2025
Same author

Performance of the ELITe InGenius system for hepatitis B virus DNA quantification.

Diagnostic microbiology and infectious disease·2025
Same journal

Burden and Distribution of Multidrug-Resistant Bacteria Among Hospitalized Patients with Cirrhosis: A Systematic Review and Meta-Analysis.

Clinics and research in hepatology and gastroenterology·2026
Same journal

Employment and Work Absenteeism in individuals living with a Vascular Liver Disease: A European multicenter study.

Clinics and research in hepatology and gastroenterology·2026
Same journal

Effect of intermittent fasting on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease.

Clinics and research in hepatology and gastroenterology·2026
Same journal

TACE-induced liver injury in hepatocellular carcinoma: mechanisms, prediction, and prevention in the era of gut microbiota and inflammasome research.

Clinics and research in hepatology and gastroenterology·2026
Same journal

€2.7 billion for the treatment of patients with pancreatic cancer: an overview and perspectives in France.

Clinics and research in hepatology and gastroenterology·2026
Same journal

"The accelerating burden of Colorectal cancer mortality With Co-documented metabolic comorbidity in the United States: A 26-year analysis of trends, disparities, and projections to 2031".

Clinics and research in hepatology and gastroenterology·2026
See all related articles

Hepatitis B surface antigen (HBsAg) quantification, alongside HBV DNA levels, helps identify patients needing antiviral therapy and predicts treatment response. This aids in managing chronic hepatitis B infection and preventing liver disease complications.

Area of Science:

  • Hepatology and Viral Immunology
  • Biomarker Discovery and Clinical Application

Background:

  • Chronic hepatitis B virus (HBV) infection affects 240 million globally, with a significant risk of liver cirrhosis and cancer.
  • Current antiviral therapies suppress HBV DNA but do not always lead to a functional cure.
  • Hepatitis B surface antigen (HBsAg) is a reliable marker for chronic HBV carriage and predicting disease progression.

Purpose of the Study:

  • To evaluate the clinical utility of quantifying HBsAg levels.
  • To assess the combined use of HBsAg quantification and HBV DNA levels for patient management.
  • To explore the role of HBsAg in predicting response to antiviral therapies, particularly pegylated interferon alpha.

Main Methods:

  • Utilized three commercially available enzyme immunoassays for HBsAg quantification.

More Related Videos

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
11:28

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Published on: March 13, 2015

Related Experiment Videos

Last Updated: May 9, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
11:28

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Published on: March 13, 2015

  • Analyzed HBsAg levels in conjunction with HBV DNA levels in patient cohorts.
  • Correlated HBsAg quantification with treatment outcomes in patients receiving pegylated interferon alpha.

    • Main Results:

    • HBsAg quantification, combined with HBV DNA levels, effectively identifies inactive HBV carriers.
    • This combined approach aids in determining the need for antiviral therapy.
    • HBsAg levels predict virological response to pegylated interferon alpha treatment in hepatitis B patients.

    Conclusions:

    • HBsAg quantification is a valuable tool in managing chronic hepatitis B.
    • It enhances the ability to stratify patients for appropriate antiviral treatment.
    • Predicting treatment response using HBsAg levels can optimize therapeutic strategies and improve patient outcomes.